| 000 | 01656 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250515034259.0 | ||
| 264 | 0 | _c20061003 | |
| 008 | 200610s 0 0 eng d | ||
| 022 | _a0001-6314 | ||
| 024 | 7 |
_a10.1111/j.1600-0404.2006.00629.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMoreira, M A | |
| 245 | 0 | 0 |
_aEffect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis. _h[electronic resource] |
| 260 |
_bActa neurologica Scandinavica _cAug 2006 |
||
| 300 |
_a109-13 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents _xpharmacology |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 |
_aChemokine CCL2 _xblood |
| 650 | 0 | 4 | _aChemokine CXCL10 |
| 650 | 0 | 4 |
_aChemokines, CXC _xblood |
| 650 | 0 | 4 |
_aChemotaxis, Leukocyte _ximmunology |
| 650 | 0 | 4 | _aControlled Clinical Trials as Topic |
| 650 | 0 | 4 |
_aDown-Regulation _xdrug effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMethylprednisolone _xpharmacology |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Sclerosis, Relapsing-Remitting _xdrug therapy |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aTilbery, C P | |
| 700 | 1 | _aMonteiro, L P | |
| 700 | 1 | _aTeixeira, M M | |
| 700 | 1 | _aTeixeira, A L | |
| 773 | 0 |
_tActa neurologica Scandinavica _gvol. 114 _gno. 2 _gp. 109-13 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1600-0404.2006.00629.x _zAvailable from publisher's website |
| 999 |
_c16456496 _d16456496 |
||